InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,490.00
(
-0.24%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,390.64
(
0.08%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DB9 post# 3236

Sunday, 04/29/2007 11:47:35 PM

Sunday, April 29, 2007 11:47:35 PM

Post# of 19309
Notes on Nuclear-Transfer License
from Start Licensing Inc. (Geron)

[Added clarity and fact that AAT herd (as well as ATryn herd) was developed using micro-injection rather than nuclear transfer.]

1. This development is neutral for GTC.

2. GTC had originally licensed the nuclear-transfer patent from Advanced Cell Technology Inc. (ACTC), but ACTC lost a patent case vs Geron and thereby lost ownership of the IP (#msg-13128835).

3. Now, GTC has licensed the same patent from Start Licensing Inc. (an affiliate of Geron) for what is presumably a similar small royalty to what GTC would have owed ACTC.

4. The Geron license has no effect whatsoever on ATryn or GTC’s development program for alpha-1 antitrypsin (AAT) because the ATryn and AAT goat herds were developed using micro-injection rather than nuclear transfer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up